Search
- From the nlmixr2 Working Group—the R-based, open-source nonlinear mixed-effects modeling package that can compete with commercial pharmacometrics tools and support regulatory submissions—now supports inter-occasion variability (IOV). r-consortium.org/posts/from-n... #rstats #submissions #pharma
- Understanding the Problems of Medical Student Exposure to Pharmaceutical Marketing Marta Makowska link.springer.com/chapter/10.1... #COI #CDoH #Pharma #MedEd
- "How do we keep some of the value in public hands so pharma products are a common good or #PublicGood rather than something that can be financialised and profited from by shareholders." #COI #CDoH #Pharma www.irishtimes.com/sponsored/20...
- China PharmaRUG’s 2025 highlights: R for modern, regulated clinical reporting—hybrid events, APAC talks, plus momentum on validation + AI governance. Read: r-consortium.org/posts/bridgi... #rstats #pharma
- Connecting pharma professionals, master’s students, and R users in one local community! Ronak Shah and the Pune R User Group are using campus-based and hybrid meetups supporting India’s fast-growing pharma + R ecosystem. r-consortium.org/posts/connec... #rstats #opensource #pharma
- nlmixr2 is becoming an R Consortium Working Group! Open-source NLME modeling in R that can compete with commercial pharmacometric tools and support regulatory submissions. More: r-consortium.org/posts/nlmixr... #RStats #pharma
- TOMORROW! 📢 R Consortium webinar: J&J’s Hybrid SAS/R FDA Submission: What Worked and Why Most pharma teams live in a mixed world of SAS and R. Go inside a successful hybrid SAS/R FDA submission and see exactly how the team made it work! r-consortium.org/webinars/jnj... #rstats #pharma #sas
- Johnson & Johnson shares how they used #R for a successful FDA submission—3 J&J researchers on open-source packages for stats and TFLs Free reg: r-consortium.org/webinars/jnj... Part of the R Submissions WG advancing R-based regulatory submissions #rstats #ClinicalTrials #Pharma #OpenSource
